Drugs / VEGF-AS
VEGF-AS
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00668499 | Apr 2008 → Apr 2011 | mesothelioma | University of Southern California | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VEGF-AS | “A Phase I/II Study of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin™) in Combination With Pemetrexed and Cisplatin” NCT00668499 ↗ |
| Known as | VEGF-Antisense Oligonucleotide | “A Phase I/II Study of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin™) in Combination With Pemetrexed and Cisplatin” NCT00668499 ↗ |
| Known as | Veglin | “A Phase I/II Study of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin™) in Combination With Pemetrexed and Cisplatin” NCT00668499 ↗ |
| Modality | Antisense oligonucleotide | “VEGF-Antisense Oligonucleotide” NCT00668499 ↗ |
| Route | Intravenous | “VEGF-AS either 100 or 200mg/m2 IV days 1-5” NCT00668499 ↗ |